- Policy
- Jeil Pharmaceutical discontinued Actos co-promotion
- by Lee, Tak-Sun Mar 27, 2023 05:56am
- Jeil, which has already launched sales of the generic drug Actozone 15mg and the combination drug Actozonemet 15/850mg from 4Q last year, is expected to launch Actozon 30mg in the reimbursement market in April. According to the industry on the 26th, Actozon 30mg will be listed at the upper limit of 940 won from April 1st. There are still fewe
- Policy
- Dupixent 200mg, newly listed
- by Kim, Jung-Ju Mar 27, 2023 05:55am
- Sanofi-Aventis Korea's severe atopic dermatitis treatment Dupixent PFS 300mg has expanded insurance coverage to pediatric and adolescent patients, and products with 200mg content will be newly listed next month with an expanded range. Taking this as an opportunity, the government is planning to expand the scope of benefits for special calculatio
- Policy
- Forxiga patent is about to expire
- by Kim, Jung-Ju Mar 24, 2023 05:48am
- As the patent for Dapagliflozin, the original drug (Forxiga), is about to expire, domestic generics of this drug will be released early next month. Accordingly, the government is swiftly proceeding with the process of calculating the drug price and additional negotiations so that the drug can be listed immediately. According to the industr
- Policy
- Dual punishment for CSO rebates passes NA committee
- by Lee, Jeong-Hwan Mar 24, 2023 05:48am
- A provision that stipulates the prohibition of doctors from receiving rebates offered by contract sales organizations (CSOs) and a plan to amend the Medical Service Act to advance regulations on medical advertisements and allow the Ministry of Health and Welfare to intervene in the Medical Advertisement Deliberation Committee passed the plen
- Policy
- Rinvoq also succeeded in expanding youth atopy benefits
- by Lee, Tak-Sun Mar 24, 2023 05:48am
- Rinvoq 15mg will be covered from April as an adolescent atopy treatment. On the same day as the biologic drug Dupixent, the youth atopic treatment benefit is applied. It is the first among JAK inhibitors to obtain reimbursement for the youth indication before Cibinqo, a competitor drug. According to the industry on the 22nd, Rinvoq SR 15mg wi
- Policy
- Pharma industry makes a request to MOTIE and MOEF
- by Nho, Byung Chul Mar 23, 2023 04:45am
- Public opinion has been rising for the government to revoke the designation of botulinum toxin as a national core technology. The rise of this public opinion brings more meaning as the request was made by Korea Pharmaceutical and Bio-Pharma Manufacturers Association, which represents the industry. Breaking away from lesser movements that
- Policy
- Legislation requiring submission of botulinum strains
- by Lee, Jeong-Hwan Mar 23, 2023 04:45am
- A bill that makes it mandatory to submit genetic information of bioterrorism infectious diseases such as botulinum toxin to domestic quarantine authorities and cancels the possession permit if not submitted did not pass the Health and Welfare Committee of the National Assembly held on the 22nd. If the bill is passed, it may lead to excessive
- Policy
- Janssen's CAR-T treatment Carvykti was approved
- by Lee, Hye-Kyung Mar 21, 2023 05:57am
- The Ministry of Food and Drug Safety (Director Oh Yu-kyung) announced that it has granted CARVYKTI, a CAR-T treatment agent, a rare drug of Jansen, a rare drug. CAR-T cells are called chimera because they modify the surface receptor to better recognize and attack cancer cells. Carvykti is an anticancer drug that injects the T cell into the pa
- Policy
- Which Vemlidy IMD among the 5 will rise to the top?
- by Lee, Tak-Sun Mar 21, 2023 05:57am
- Although failing to receive reimbursement in advance, many Vemlidy IMDs are awaiting entry into the Korean market. All the drugs are incrementally modified drugs that were developed with different salt formations. According to industry sources on the 20th, 5 more companies are waiting to enter the market with Vemlidy latecomers. These com
- Policy
- Erleada applied for health insurance in April
- by Lee, Tak-Sun Mar 20, 2023 05:51am
- As this drug is an upgraded version of prostate cancer treatment, which is increasing every year, many patients are expected to benefit if health insurance benefits are applied. On the 16th, the HIRA foretold the reimbursement standards for anticancer drugs, which include the establishment of new reimbursements for ADT and combination therapy
